Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression

BACKGROUND: The enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy for fabI have been shown to confer resistance in S. aureus strains i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Genomics
Autors principals: Grandgirard, Denis, Furi, Leonardo, Ciusa, Maria Laura, Baldassarri, Lucilla, Knight, Daniel R, Morrissey, Ian, Largiadèr, Carlo R, Leib, Stephen L, Oggioni, Marco R
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4415318/
https://ncbi.nlm.nih.gov/pubmed/25924916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12864-015-1544-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars